CLINICAL TRIALS BASED
ON MUTATIONS
Molecular-matched trial enrollment is not a last resort for patients with targetable mutations and no approved option. It is often the most clinically appropriate treatment available.
analyticsAt a Glance
- check_circleMutation-matched trials use biomarker data to target specific genetic alterations
- check_circleBasket trials enrol patients by mutation type across different cancer types β not just by diagnosis
- check_circleEGFR, KRAS G12C, BRAF V600E, NTRK, RET, and MET are common trial targets
- check_circleNGS testing is the first step β patients need to know their mutation profile to find matched trials
Types of Mutation-Matched Trials
Basket Trials
Enrol patients across cancer types based on a shared molecular alteration. A patient with an NTRK fusion in a salivary gland cancer and one in a colorectal cancer qualify for the same trial. The shared molecular feature is the eligibility criterion. The original trials that produced current tumour-agnostic approvals were basket trials.
Umbrella Trials
Enrol one cancer type and direct patients to different treatment arms based on molecular profile. Common in lung cancer. Handles the complexity of multiple actionable alterations within a single cancer type efficiently.
Phase I Dose-Escalation Trials
First-in-human testing of a targeted agent. Typically for patients who have exhausted standard options. May offer access to genuinely novel mechanisms well before any commercial approval for patients with the specific target alteration.
NCI-MATCH and Platform Programmes
Systematically screen tumours and assign patients to multiple simultaneous treatment arms. Large infrastructure, broad alteration coverage, multiple cancer types. Important source of trial access particularly for uncommon alterations.
Frequently Asked Questions
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination β travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Want to Find Mutation-Matched Clinical Trials for Your Alteration?
CancerFax identifies currently enrolling basket and umbrella trials matched to your specific molecular findings and prior treatment history.
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified oncologist before making treatment decisions.